Abstract
Since its introduction 10years ago, the urinary PCA3 test was evaluated in several studies that allowed demonstration of its diagnostic value when predicting prostate biopsy outcome. Its good specificity, notably when compared to seric PSA, offers to the urologist the opportunity to better evaluate whether prostate biopsies are warranted, especially in patients with at least one set of previous negative biopsies. Several points remain to be determined such as its true influence on prostate decision making in clinical practice and the resulting medico-economic benefit. The place of the urinary PCA3 test among other developing prostate cancer biomarkers, notably PHI index and urinary TMPRSS2:ERG fusions, has also to be defined.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
